BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,124 filers reported holding BAXTER INTL INC in Q2 2020. The put-call ratio across all filers is 0.74 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $247,710,566 | -17.4% | 6,563,608 | -0.3% | 1.30% | -10.2% |
Q2 2023 | $299,844,849 | +11.1% | 6,581,318 | -1.1% | 1.45% | +1.0% |
Q1 2023 | $269,827,347 | -51.3% | 6,652,548 | -38.8% | 1.44% | -55.1% |
Q4 2022 | $553,844,048 | -13.4% | 10,866,079 | -8.5% | 3.20% | -15.8% |
Q3 2022 | $639,644,000 | -23.5% | 11,876,040 | -8.8% | 3.80% | -16.7% |
Q2 2022 | $836,163,000 | -34.3% | 13,018,264 | -20.6% | 4.56% | -21.8% |
Q1 2022 | $1,271,794,000 | -30.0% | 16,401,780 | -22.5% | 5.82% | -22.0% |
Q4 2021 | $1,817,350,000 | +9.0% | 21,171,371 | +2.1% | 7.47% | +7.7% |
Q3 2021 | $1,667,946,000 | -1.4% | 20,737,864 | -1.3% | 6.93% | -1.1% |
Q2 2021 | $1,690,992,000 | -4.4% | 21,006,109 | +0.1% | 7.01% | -5.5% |
Q1 2021 | $1,769,716,000 | +26.6% | 20,983,112 | +20.4% | 7.42% | +18.9% |
Q4 2020 | $1,398,147,000 | +46.6% | 17,424,560 | +46.9% | 6.24% | +23.3% |
Q3 2020 | $953,613,000 | +4.4% | 11,857,911 | +11.8% | 5.06% | -3.9% |
Q2 2020 | $913,185,000 | +10.7% | 10,606,094 | +4.4% | 5.27% | -10.0% |
Q1 2020 | $824,943,000 | +44.7% | 10,160,652 | +49.0% | 5.86% | +60.6% |
Q4 2019 | $570,105,000 | – | 6,817,806 | – | 3.65% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |